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Abstract
Background: There is a need for drug delivery systems (DDS) that can enhance cytosolic delivery of anti-cancer drugs
trapped in the endo-lysosomal compartments. Exposure of cells to specific photosensitizers followed by light exposure
(photochemical internalization, PCI) results in transfer of agents from the endocytic compartment into the cytosol.
Methodology and Principal Findings: The recombinant single-chain fusion construct scFvMEL/rGel is composed of an
antibody targeting the progenitor marker HMW-MAA/NG2/MGP/gp240 and the highly effective toxin gelonin (rGel). Here
we demonstrate enhanced tumor cell selectivity, cytosolic delivery and anti-tumor activity by applying PCI of scFvMEL/rGel.
PCI performed by light activation of cells co-incubated with scFvMEL/rGel and the endo-lysosomal targeting
photosensitizers AlPcS2a or TPPS2a resulted in enhanced cytotoxic effects against antigen-positive cell lines, while no
differences in cytotoxicity between the scFvMEL/rGel and rGel were observed in antigen-negative cells. Mice bearing well-
developed melanoma (A-375) xenografts (50–100 mm
3) were treated with PCI of scFvMEL/rGel. By 30 days after injection,
,100% of mice in the control groups had tumors.800 mm
3. In contrast, by day 40, 50% of mice in the PCI of scFvMEL/rGel
combination group had tumors,800 mm
3 with no increase in tumor size up to 110 days. PCI of scFvMEL/rGel resulted in a
synergistic effect (p,0.05) and complete regression (CR) in 33% of tumor-bearing mice (n=12).
Conclusions/Significance: This is a unique demonstration that a non-invasive multi-modality approach combining a
recombinant, targeted therapeutic such as scFvMEL/rGel and PCI act in concert to provide potent in vivo efficacy without
sacrificing selectivity or enhancing toxicity. The present DDS warrants further evaluation of its clinical potential.
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Introduction
The emergence of membrane impermeable or macromolecular-
based biopharmaceuticals with intracellular targets has initiated a
need for smart drug delivery systems (DDS). Sequestration and
degradation of such anti-cancer therapeutics in endosomes or
lysosomes is a major barrier for efficient cancer therapy [1]. To
achieve sufficient cytosolic or nuclear concentrations in the target
cells, high doses of anti-neoplastic drugs are frequently adminis-
tered leading to undesired adverse effects. Therefore, current
efforts in cancer pharmaceutics include the development of
targeted DDS in which the drug of interest is activated only in
the malignant tissue and thereby sparing normal tissue.
We have established photochemical internalization (PCI) as a
novel DDS for the controlled cytosolic release of macromolecules or
chemotherapeutic agents that are sequestered in endo-lysosomal
compartments. PCI is based on photodynamic therapy (PDT), a
photochemical method generating reactive oxygen species (ROS)
after confined light activation of a tumor-accumulating photosen-
sitizer [2–4]. The main PDT-induced ROS product is singlet
oxygen, which can destroy a number of biomolecules including
lipids and proteins of the endo-lysosomal membranes [5,6]. Hence,
PCI provide a unique, controlled, spatio-temporal DDS in which
intracellular molecules held in the endosomal/lysosomal compart-
ment are released to the cytosol by the effects of PCI.
Theprogenitormarkergp240,alsoknownasHMW-MAA/NG2/
MPG/MCSP, has emerged as a potential target for cancer therapy
due to its pro-survival, growth and invasion signaling in several
cancers types that exert broad resistance profiles against chemother-
apy [7–10]. gp240 is expressed in .80% of human melanomas [11]
and 67% of lobular breast carcinomas [12] and has been associated
with angiogenesis in brain tumors [13] where it seems to be expressed
on hematopoietic stem cell-derived pericytes [14]. In addition, gp240
is recognized as a marker for multipotent early oligodendrocyte
progenitors in normal CNS [15,16] and its increased co-expression
with CD44 has been proposed as progressive marker of malignant
gliomas [17]. Moreover, gp240 correlates with poor clinical outcome
in childhood acute myeloid leukemias [7].
The antibody ZME-018 has been used in numerous studies for
imaging [18] and as a carrier for development of gp240-targeted
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chemical conjugates of full-length ZME-018 and toxins such as
rGel, nGel and TNF. In addition, recombinant single-chain
antibodies targeting gp240 and have been fused to payloads such
as rGel, TNF and granzyme B [19–21]. The scFvMEL/rGel
fusion construct has been well-characterized and demonstrates
impressive and selective cytotoxic effects against tumor cells in
culture and against tumor xenograft models.
We proposed that PCI may augment the biological activity of
many agents including tumor cell targeted therapeutics and fusion
constructs. This study describes the first report of the use of PCI as
a modality to enhance the delivery of a tumor-targeting drug in
vivo. PCI was found to induce cytosolic release of the internalized
fusion construct and strongly potentiated the anti-tumor effect of
the recombinant fusion toxin scFvMEL/rGel against tumor
xenografts. There were no adverse side effects observed in nude
mice and these studies clearly demonstrate that using PCI as a
modality may greatly improve the efficacy of cell-targeted
therapeutic agents.
Results
Cytosolic delivery of photosensitizer and scFvMEL/rGel
upon light exposure
Cytosolic release of AlPcS2a post light exposure (PDT) was
evaluated by epi-fluorescence microscopy of A375-GFP cells,
while recombinant gelonin (rGel) fused to the scFv-fragment
(scFvMEL/rGel), was detected by ICC. Granular red fluorescence
(.660 nm) of AlPcS2a characteristic for endocytic vesicles was
detected in the A375-GFP cells (Figure 1A). Red light exposure of
the AlPcS2a-treated A375-GFP cells resulted in an immediate
relocalization of the photosensitizer throughout the cytosol of the
cells. No detectable overlap of fluorescence from the photosensi-
tizer (red) and Hoechst 33342 (blue) was detected, indicating
extranuclear localization of AlPcS2a.
Prior to PCI of scFvMEL/rGel, a distinct granular extranuclear
localization of the rGel was detected by ICC of A-375 cells
(Figure 1B). Thirty minutes after PCI of scFvMEL/rGel, a
significant light-dose-dependent redistribution of rGel to the whole
Figure 1. Photochemical-mediated endo-lysosomal release and cytosolic delivery of photosensitizer and scFvMEL/rGel. A375-GFP
cells were incubated for 18 h with 5 mg/ml AlPcS2a, washed twice and chased in drug-free medium for 4 h. 30 min prior to microscopy, cells were
incubated with 5 mg/ml Hoechst 33342. A, Fluorescence of EGFP, Hoechst 33342 and AlPcS2a and merged (E+H+A) in vital cells prior to (upper panels)
and 1 min post 10 sec of microscopy red light exposure (590–650 nm) with respectively merged micrographs and corresponding phase contrast (mid
panels). Structure formula of AlPcS2a in left lower panel. B, A-375 cells were co-incubated for 18 h with 80 nM scFvMEL/rGel and 5 mg/ml AlPcS2a,
washed twice and chased in drug-free medium for 4 h prior to light exposure and further incubated at 37uC for 30 min prior to ICC detection of rGel.
Right panel, negative controls included rabbit IgG isotype.
doi:10.1371/journal.pone.0006691.g001
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the cytoplasm and nucleoplasm. Positive and negative controls to
verify specific detection of rGel, as described in Materials and
Methods, gave satisfactory results.
Cytotoxicity of PCI of scFvMEL/rGel in A-375 melanoma
cells
The measurements of cytotoxicity of PCI were mostly
performed by the MTT assay, however confirmed by either
clonal cell survival or by the assessment of GFP-signals since
leakage of GFP has been reported to correlate with cell death
[22,23].
The photochemically induced relocalization of rGel (Figure 1B)
is in accordance with the enhanced cytotoxicity observed when the
photochemical treatment was combined with scFvMEL/rGel
treatment in A375-GFP (Figure 2A). PCI performed by combining
subtoxic photochemical and scFvMEL/rGel treatment doses
resulted in a substantial reduced A375-GFP cell viability as
measured by the MTT cell viability assay 48 hrs after light
exposure. Similar results were obtained in the maternal A-375 cell
line after PCI of scFvMEL/rGel using either TPPS2a (Figure S1)
or AlPcS2a (data not shown) as photosensitizers. No differences in
toxicity were observed between PCI of non-conjugated nGel and
rGel in the A-375 cells and the cytotoxic effects were substantially
lower than after PCI of scFvMEL/rGel. Exposure to light in the
absence of an externally added photosensitizer did not induce any
decrease in cell viability in cells treated with scFvMEL/rGel in
both A375-GFP (Figure 2A) and A-375 cells (data not shown).
The photochemical treatment (i.e. PDT) is known to induce a
rapid cell inactivation causing cell death within 24 hrs after light
exposure [24]. However, in contrast to the MTT cell viability
assay performed 48 hrs after light exposure, 24 hrs after the light
exposure only a modest attenuation of cell viability was observed
by scFvMEL/rGel or rGel in photochemically treated cells as
compared to PDT (Figure S2). Similarly, the GFP-signal was lost
between 24 and 48 hrs after PCI in A375-GFP cells (Figure 2B–H,
Figure S3). Thus, the MTT viability assay correlated with the loss
of GFP in the A375-GFP cells. No increase in cell cytotoxicity was
observed by postponing the MTT analysis from 48 to 72 hours
after light exposure (data not shown). Increased cytotoxic activity
measured 48 hours as compared to 24 hours after light exposure
indicates that the enzymatic activity of rGel, either as native toxin
or as fusion toxin, is a relative slow catalytic process in the cells.
Clonal cell survival data analysis confirmed the synergistic effect of
PCI of scFvMEL/rGel in the A-375 cells (data not shown).
Previously, we demonstrated, in vitro and in vivo, that the
photochemical delivery of nGel may be performed by adminis-
trating nGel shortly after the photochemical treatment [25,26].
However, the photochemical enhancement of scFvMEL/rGel
toxicity was substantially lower when the immunotoxin was
delivered directly after the light exposure of the A-375 cells
(Figure S4). This is assumed to be due to a photochemical damage
to the gp-240 receptor in accordance with the observed
photochemical inactivation of EGFR [27,28].
Cytotoxicity after PCI of scFvMEL/rGel in different cancer
cell lines correlates with the expression of the progenitor
marker HMW-MAA/NG2/MPG/gp-240
To demonstrate a general applicability of the PCI-based DDS
PCI of scFvMEL/rGel were evaluated in two other cell lines of
different cancer origins: Lobular breast carcinoma (MA11) and
malignant glioblastoma (U87MG) from brain cancer, the latter
shown to express NG2 [9]. Expression of the target receptor on
MA11 cells was confirmed by detecting receptor-binding of
scFvMEL/rGel by using a primary rabbit antibody against
gelonin and an Alexa488 labeled secondary goat anti rabbit
antibody, while control experiment using incubation of the
primary and the secondary antibody alone resulted in no
fluorescing signals (Figure S5). PCI in these cell lines resulted in
a strongly enhanced light-dose and toxin-dose dependent cytotox-
icity compared to either PDT alone or fusion toxin treatment
alone (Figure 3). No dark toxicity of PS alone or in combination
with the fusion toxin was observed in both cell lines (Figure 3A).
As control for gp240-targeting, we compared the cytotoxicity of
scFvMEL/rGel with rGel in the gp240 negative T24 bladder
carcinoma cell line. No differences in cytotoxicity were observed
between the toxin and the immunotoxin treatment in the absence
of photochemical treatment (Figure 4A). Accordingly, no en-
hancement of cytotoxicity was observed after PCI of scFvMEL/
rGel as compared to PCI of rGel in the gp-240-negative T24 cells
(Figure 4B).
PCI-enhanced tumor-targeting and anti-tumor activity of
scFvMEL/rGel without apparent adverse effects
Subcutaneous A-375 xenografts were used to evaluate the
therapeutic effect of PCI of scFvMEL/rGel. PCI was performed
by single, systemic administration of AlPcS2a and scFvMEL/rGel
prior to light exposure confined to the s.c. tumor as compared to
multiple injections which is standard for immunotoxin treatments,
including previous work with scFvMEL/rGel [19].
The therapeutic potential of PCI of scFvMEL/rGel on A375
xenograft tumors was assessed over time by measuring the effect
on tumor growth. The tumor response to the various treatments is
presented in a Kaplan-Meier plot in Figure 5. scFvMEL/rGel was
found to delay the time for the A-375 xenograft to reach 800 mm3
by 5 days (not significant, Tables 1 and 2). There was a slightly
longer delay (10 days), but not significant, in tumor growth of
tumors treated with both scFvMEL/rGel and AlPcS2a (Tables 1
and 2). Previous studies on several tumor models have shown that
AlPcS2a in the absence of light treatment has no effect on tumor
growth [3,26,29,30]. However, the animals are treated and tumors
measured under subdued light and it cannot be excluded that the
light exposure of the animals during these procedures is sufficient
to induce a moderate growth delay in the presence of systemically
delivered scFvMEL/rGel. The PDT dose used in this study
delayed the tumor growth by approximately 7 days, not
significantly different from the growth of the untreated tumors
and the other treatments except for the PCI treatment (Tables 1
and 2). The treatment with PCI of scFvMEL/rGel was
substantially more effective than all other treatments, inducing a
significantly longer growth delay (p#0,004, Table 2) with 50% of
the tumors not reaching the endpoint of 800 mm3 (Figure 5). The
PCI of scFvMEL/rGel treatment was found to act in a synergistic
manner (p,0.05) as compared to the expected sum of the
individual treatments scFvMEL/rGel and PDT with R=1.15,
indicating that the tumor growth delay by PCI of scFvMEL/rGel
was more that twice as long as expected by an additive effect. A
complete regression (CR) of the A-375 tumors was obtained in
33% of the mice treated with PCI of scFvMEL/rGel.
For the assessments of potential adverse effects, we measured the
body weight of the animals, assessed skin tissue regeneration and
observed the movement and behavior of the animals after the
different treatment regiments. No adverse events were observed after
treatment as assessed by measuring body weight (Figure 5B and C,
Figure S6), or change in behavior and locomotion of the mice (data
not shown). These results indicate that the normal tissue, including
Light-Enhanced Drug Delivery
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tissue that surrounds the tumor was apparently unaffected by PCI.
Edema and erythema of the tumor tissue was observed
indicating inflammation due to the photosensitization process.
However this effect reversed 48–72 hours after light exposure, in
accordance with reported response to PDT [31].
The skin of the mice and in particular the skin over the A-375
tumors that were treated with PCI of scFvMEL/rGel was
observed over time. A non-ulcerating wound appeared on the
light-exposed skin. However, the skin regenerated post PCI,
leaving a small scar one week after treatment, which disappeared
two weeks later (Figure 6).
Discussion
The use of molecular cancer therapeutics is often limited by life-
threatening systemic side effects due to high drug dosage and non-
site-specific targeting [32]. In addition, endo-lysosomal sequestra-
tion and degradation of anti-cancer drugs is often a major obstacle
for successful therapeutical outcome. Hence, there is a need for
Figure2.EnhancementofcytotoxicityandreductionofEGFPsignals byPCIofscFvMEL/rGelinA375-GFPmelanomacells.A,Viabilityof
A375-GFP cells subjected to PCI of scFvMEL/rGel (red triangles), PDT (black dots) or scFvMEL/rGel only (green squares). Cells were incubated with 5 mg/
ml AlPcS2a with or without 100 nM scFvMEL/rGel for 18 h, followed by 3 times wash and 4 h chase in drug-free medium prior to exposure to increasing
light exposure of cells (15 minutes=1.35 J/cm
2). Cytotoxicity was assessed by the MTT assay 48 h post light exposure. Bars, SD. B, Fluorescence of EGFP
and Hoechst 33342 in an untreated A375-GFP cell. C, Phase contrast of a cell treated with PCI of scFvMEL/rGel (LD90, 0.54 J/cm
2) with corresponding
fluorescence of AlPcS2a (D), Hoechst 33342 (E), EGFP (F) and a merge of D,E and F (G) 48 h post light exposure. H, A375-GFP cells 24 and 48 hours post
either PDT (LD50, 1.35 J/cm
2) or PCI of scFvMEL/rGel (LD90, 0.54 J/cm
2) as compared to untreated control cells (Ctr).
doi:10.1371/journal.pone.0006691.g002
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from endocytic drug entrapment [33]. Our labs have indepen-
dently developed two different DDS for the specific targeting of
cancer, the use of recombinant fusion toxins [19,34] and
photochemical internalization (PCI) for the cytosolic delivery of
endo-lysosomal sequestered therapeutics [2,4]. The overall aim of
this study was to explore the concept of merging our two DDS
modalities by applying PCI to cells or tumor-bearing mice treated
with the fusion toxin scFvMEL/rGel. scFvMEL/rGel targets the
progenitor marker HMW-MAA/NG2/MPG/gp-240, which is
expressed in several types of cancers and is associated with tumor
growth, metastasis and chemotherapeutic resistance [9]. In
addition, we wanted to assess the potential of the present DDS
to minimize possible adverse effects after treatment.
Here we report that PCI strongly enhance the cytotoxicity of
scFvMEL/rGel in several gp-240 expressing cancer cell lines; A-
375, MA11 and U87 in contrast to the gp-240-negative T24 cells.
These findings together with the data showing that PCI of the
targeting toxin is by far much more cytotoxic than the PCI of non-
conjugated toxin demonstrates that the high specificity and
efficacy of PCI of scFvMEL/rGel.
In the present study it has for the first time been shown that PCI
is an efficient technology for enhancing the therapeutic efficacy of
a systemically delivered targeting therapeutics. Using the A-375
xenograft as model, potent anti-tumor effects were obtained after
PCI of scFvMEL/rGel at concentrations considerably below a
maximal tolerable dose compared to a previous study where the
fusion toxin alone was administered by multiple injections [19].
Improved treatment specificity, i.e. increased therapeutic efficacy
and reduced side effects, is the major advantage of the DDS
presented in this study. Previously, we have demonstrated in vivo
PCI of non-conjugated gelonin after direct intratumoral injection
of the protein toxin at relatively high concentrations as a proof-of-
concept [3,26,29]. In addition, PCI mediated delivery of other
non-targeting therapeutics has been demonstrated in vivo, i.e.
bleomycin, p53-based gene therapeutics and siRNA [30,35–
37].The DDS system presented here may therefore reduce the
dosage of anti-cancer therapeutics that is needed to achieve a
satisfactory outcome.
Cancer therapy using toxin conjugates usually requires
fractionated treatment, which may lead to the development of
neutralizing antibodies and often inflammatory adverse effects
[38]. Another obstacle in using macromolecular-based therapeu-
tics is the slow penetration of the drug throughout solid tumors due
to sterical hindrance in the extracellular matrix and elevated
interstitial fluid pressure resulting in inhomogeneous distribution
and low intracellular levels of the drug [39]. The PCI-technology
as demonstrated here is based on low-dose single injections of the
two drugs needed, i.e. injection of the photosensitizer and the
targeting toxin conjugate, prior to the light activation. The
Figure 3. PCI of scFvMEL/rGel in MA11 breast carcinoma cells
(A) and U87 malignant glioma cells (B). The cells were incubated
with 5.0 mg/ml AlPcS2a+/216.5 nM scFvMEL/rGel or 16.5 nM rGel for
18 hours and then washed twice and chased in drug-free medium 4 h
prior to red light exposure. MTT assay was performed 48 hours post
light. Experiments with triplicates were reproduced at least twice. Bars,
SE.
doi:10.1371/journal.pone.0006691.g003
Figure 4. Control experiments in gp240-negative bladder
cancer cell line T24. A, Cells were treated with either rGel or
scFvMEL/rGel for 18 h with increasing toxin concentrations. B, AlPcS2a-
PCI of scFvMEL/rGel or rGel in T24 cells. The cells were treated and
assessed as described in figure 3. Bars, SE.
doi:10.1371/journal.pone.0006691.g004
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demonstrated in this study indicates that PCI of targeting fusion
toxins provide significant improvement in anti-tumor specificity
and activity, while at the same time sparing the normal tissue.
On the basis of the data presented in this study, we suggest that
PCI provides a triple tumor-targeting DDS due to; 1) The
targeting ability of the antibody fragment of the fusion toxin
having selectivity against HMW-MAA/NG2/MPG/gp-240 ex-
pressing cancer cells; 2) A preferential accumulation and retention
in malignant tissues of the photosensitizers [40], which is non-toxic
in the dark and become activated only in the presence of light; 3)
Confined light exposure of the tumor area with wavelengths
matching the absorption of light by the PS. Indeed, the specificity
of the PCI technology was confirmed by demonstrating no weight
loss of animals or other side effects that were subjected to PCI of
scFvMEL/rGel.
A general limitation of the PCI technology lays in the restriction
of the penetration depth of the light in the tissue and the fact that
this is a locoregional treatment. However, this problem may be
solved by the use of optical fibers that can be inserted into the
tumor tissue, as already performed during interstitial PDT [41].
Moreover, promising systemic effects reported recently by
independent laboratories show that the PDT of cancer in different
animal models induce an activation of systemic long-term memory
T-cells and thereby have tumor-vaccinating effects [42]. Recently,
this was clinically supported where untreated distant tumors
regressed after local PDT of a patient with recurrent angiosarcoma
[43]. The disseminated tumor cells and micro-metastasis may also
be controlled by the targeting toxin. The most common side effect
of PDT is photosensitivity of the skin, and hence we anticipate that
this could also be the major side effect of the treatment presented
in this work.
Figure 5. PCI of scFvMEL/rGel in A-375 xenografts. A, Kaplan Meier plot of treatment groups as indicated in the figure. Nude mice with s.c.
growing A-375 (50–100 mm3) tumors were given AlPcS2a (5 mg/kg i.p.) with or without scFvMEL/rGel (2 mg/kg i.v) administered 48 and 24 hours
prior to laser light exposure (day 0), respectively. The light dose was 20 J/cm
2 with an irradiance of 100 mW/cm
2. n, number of animals in each group.
B, Weights of the mice treated with PCI of scFvMEL/rGel as compared with non-treated animals. Range of weights at treatment start were 22–29 g.
Weight data for the other groups are shown in Figure S6.
doi:10.1371/journal.pone.0006691.g005
Table 1. Mean time for A-375 tumors to reach the endpoint of 800 mm
3.
Groups Treatment No. of animals Mean time to reach 800 mm SE
1 untreated 14 20,0 2,1
2 scFvMEL/rGel 11 24,9 2,9
3 scFvMEL/rGel+AlPcS2a 11 29,9 4,9
4 PDT 12 26,9 2,8
5 PCI of scFvMEL/rGel 12 176,5 54,4
Mean time for A-375 tumors to reach the endpoint of 800 mm
3 after various specified treatments based on Kaplan-Meier survival analysis in SPSS where all animals in
the groups are included. SE represents standard error.
doi:10.1371/journal.pone.0006691.t001
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for the treatment of amelanotic melanoma (AM) in situ [44].
Interestingly, among melanomas with stem cell properties, the
amelanotic cells are thought to be less differentiated and more
aggressive than the melanotic cells [45]. Thus, based on the
promising in vivo data obtained in this report, PCI of scFvMEL/
rGel should be further explored as a potential treatment for
HMW-MAA/NG2/MPG/gp-240 expressing cancers. A phase I
clinical trial based on PCI of bleomycin has recently been
approved for several indications including AM. PCI of scFvMEL/
rGel could be considered as an interesting follow up for treatment
of AM.
In conclusion, the present study demonstrates for the first time
the tumor-targeting potential of PCI as a novel modality which
may be deployed in combination with other targeted therapeutic
agents. PCI of fusion toxins is a promising and innovative non-
invasive, in situ treatment of cancer. Lower drug doses used to
achieve anti-cancer effects made possible by the present PCI
technology might lead to significant reduction of drug or
treatment-induced adverse events in humans. These data appear
to warrant further investigations toward future clinical applications
of the PCI drug delivery system.
Materials and Methods
Cell lines and cell culture conditions
All cell lines were of human origin and the following were
purchased from ATCC (American Type Culture Collection,
Manassas VA): A-375, non-pigmented malignant skin melanoma
(CRL-1619); transitional cell carcinoma of the bladder T24 (HTB-
4) and U87MG, glioblastoma (HTB-14). In addition, GFP-
expressing A-375 cells (A375-GFP) were established as described
[20]. The lobular breast carcinoma cell line MA11 [46], was
provided by Dr. Geir Olav Hjortland, Dept. of Tumor Biology,
Norwegian Radium Hospital. Cells were tested as mycoplasma
free.
Chemicals
Photosensitizers Aluminum phthalocyanine with two sulfonate
groups on adjacent phenyl rings (AlPcS2a) (Frontier Scientific, Salt
Lake City, Utah) and meso-tetraphenylporphine with two
sulfonate groups on adjacent phenyl rings (TPPS2a) (PCI Biotech
ASA, Oslo, Norway) was prepared and stored as earlier described
[47,48]. Hoechst 33342 was obtained from Sigma (St. Louis,
MO).
Production of recombinant fusion toxin
A single-chain anti-HMW-MAA/NG2/MPG/gp-240 antibody
(scFvMEL) was fused to recombinant gelonin (rGel), expressed in
bacterial cultures, purified to homogeneity and characterized for
biological activity as previously described [19].
Fluorescence microscopy
Phase contrast and fluorescence microscopy of cells incubated
with different dyes were performed by means of a Zeiss Axioplan
epi-fluorescence and phase contrast microscope (Zeiss, Oberko-
chen, Germany) as described [47,48]. Immunocytochemical
detection of rGel by the DakoCytomation system in A-375 cells
was performed by using an Olympus AX70 microscope.
Light sources
In vitro light exposures of tumor cells were performed by using
LumiSourceTM lamp (PCI Biotech, Oslo, Norway) emitting
either blue (11.7 mW/cm
2) or red light (1.5 mW/cm
2)a s
previously described [47,49]. The in vivo illumination was
performed with a 300 mW diode laser, Ceralas I 670 (CeramOp-
tec GmbH, Bonn, Germany) emitting 670 nm light.
In vitro drug delivery by PCI
Cells were seeded in 96-well plates (Nunc, Roskilde, Denmark)
at 3500 (T24), 4000 (A-375/A375-GFP, MA11) or 8000 (U87MG)
cells/cm
2 and allowed to attach to the substratum at 37uC, either
for 6 hours or over night. scFvMEL/rGel was then co-incubated
with TPPS2a or AlPcS2a for 18 hours. This was followed by a
three-time drug-free medium wash of the cells and a further
4 hour drug-free medium chase. Subsequently, the cells incubated
with TPPS2a or AlPcS2a were subjected to light exposure by using
the blue or the red light LumiSource respectively.
Cytotoxic assays
Cytotoxicity was evaluated using the MTT assay 48 h post PCI,
and when possible, confirmed by clonal cell survival as previously
Table 2. Statistical significance analyses (p-values) to reveal
differences in therapeutic effect between various treatment
regimens on the A-375 tumors.
Treatment groups
Groups Treatment 1 2 3 4
1 untreated
2 scFvMEL/rGel 0,348
3 scFvMEL/rGel+AlPcS2a 0,036 0,385
4 PDT 0,132 0,493 0,796
5 PCI of scFvMEL/rGel ,0,001 0,001 0,003 0,004
The values are based on paired log rank analyses of the time for the A-375
tumors to reach 800 mm
3.
doi:10.1371/journal.pone.0006691.t002
Figure 6. Tumor response and skin regeneration post PCI of
scFvMEL/rGel. Two mice (#1 and #2) with ,75 mm3 A-375 tumors
at day 0 were further assessed at day 1, 5 and 19 post PCI. Both mice
obtained CR and excellent wound repair after PCI of scFvMEL/rGel (still
at day 110) as compared to a untreated control mouse (Ctr) having a
tumor which reached .1000 mm3 at day 19 (,13-fold tumor increase
compared to day 0).
doi:10.1371/journal.pone.0006691.g006
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with the assay [50], however the agents used in this work do not
have any absorbance at 570 nm. In addition, PCI of scFvMEL/
rGel was qualitatively assessed by fluorescence microscopy of the
A375-GFP cells post treatment, since cellular leakage of GFP due
to plasma membrane damage has been established as an method
for assessment of cell death [22,23].
Immunocytochemistry (ICC)
A-375 cells (10000 cell/well) were seeded out in 16-well
chamber slides from Lab-Tek (Nunc) and treated with PCI as
described above. Cell plasmamembranes were stripped with
100 ml 0.1 M Glycine (pH 2.5) in 0.5 M NaCl for 5 minutes at
37uC, neutralized with 100 ml 0.5 M Tris-HCl (pH 7.4) for 5
minutes at 37uC. The cells were subsequently fixed with 4%
buffered formalin at room temperature and stained using the Dako
EnVision+ System HRP-DAB (K4011, DakoCytomation, Car-
pinteria, CA). Cells were treated with 0.03% hydrogen peroxide
for 5 min and then incubated with a polyclonal rabbit-anti-gelonin
IgG (1:400, 0.5 mg/ml, National Institute of Health, Oslo,
Norway) for 30 min at room temperature. The cells were then
incubated with Peroxidase-labeled polymer conjugated to goat
anti-rabbit IgG for 30 min and stained for 10 min with 393-
diaminobenzidine tetrahydrochloride, counterstained with hema-
toxylin, dehydrated, and mounted in Diatex (Sigma). The
antibody has previously been validated for detection of native
gelonin in tumors [29].
Animal model
Female BALB/c (nu/nu) nude mice were bred at the Animal
Department of the Norwegian Radium Hospital and maintained
under specific pathogen-free conditions, with food and water
supplied ad libitum. Housing and all procedures involving animals
were performed according to protocols approved by the
institutional animal care and use committee, in compliance with
the Norwegian Animal Research Authority’s guidelines. The mice
were on average 20 to 25 g (5–8 weeks old) at the start of the
experiments.
In vivo delivery of scFvMEL/rGel by PCI
Cultured subconfluent A-375 cells were prepared for s.c.
injection as previously described [19]. Treatment commenced at
an A-375 tumor volume of 50–100 mm3. Forty-eight hours prior
to PCI-treatment, the mice were subjected to i.p. injection of
5 mg/kg bw of AlPcS2a followed the next day by i.v. administra-
tion of 2 mg/kg bw of scFvMEL/rGel 24 h prior to 670 nm laser
exposure at an irradiance of 100 mW/cm
2 and the total dose of
20 J/cm
2. To avoid undesired light exposure of normal tissue
during the light exposure, the whole body was covered with
aluminum foil, except for the skin over the tumor area and a few
millimeter rim of normal skin surrounding the tumor. The tumor
volume was calculated using the following formula:
V~ W2|L ðÞ =2
according to the US National Cancer Institute protocols where W
is the with and L the length of the tumors measured 2 or 3 times
per week with a digital caliper. The animals were euthanized by
cervical dislocation if the tumor volume exceeded 1000 mm
3.
Statistical analysis
In vitro and in vivo data were expressed as mean+/2SD or +/
2SE, respectively. All in vitro experiments are based on triplicates
and reproduced at least twice. Representative results are depicted.
Differences between groups were in vitro estimated by Student’s t-
test. All differences were deemed significant at a level of p#0.05.
Analyses were performed by the Sigma Plot Software Package.
The tumor growth data were subjected to survival analysis,
using the day when the tumor volume supersedes the volume
Vcrit=800 mm3 defined as the failure time, and the duration of
the experiment as the censoring time, if the tumor does not obtain
this volume. Statistical differences in treatment response were
evaluated by pair wise log-rank analyses in SPSS 15.0.
Because both scFvMEL/rGel and PDT induced a delay in
tumor growth, documentation of synergism requires more detailed
analyses, as previously described [30]. The documentation of
synergy is based on a log-logistic survival function. Synergy or
antagonism is regarded as statistically significant when the
additional interaction variable, b3, is significantly different
(p,0.05) from the sum of the individual survival variables,
b12=b1+b2. The synergistic effect can be described by R=b3/
(b1+b2), where R=0 describes additivity and R,0 and R.0
respectively, when significant, describes antagonism and syner-
gism. As an example R=0.5 describes a synergy effect of the same
order of magnitude as 50% of the two treatments combined.
Supporting Information
Figure S1 TPPS2a-PCI of increasing doses of toxins. Light-dose
and toxin concentration-dependent reduction of cell viability post
PCI of scFvMEL/rGel in A-375 using TPPS2a as photosensitizer.
A, PCI of 100 nM native (n), recombinant (r) gelonin (rGel) or
scFvMEL/rGel after 18 hours co-incubation with 0.2 mg/ml
TPPS2a and 4 hours chase in drug-free medium. B, Experiments
with triplicates were reproduced at least twice. MTT assay was
performed 48 hours post light exposure. Bars, SD.
Found at: doi:10.1371/journal.pone.0006691.s001 (0.05 MB PPT)
Figure S2 Cytotoxic response 24 hours post light exposure.
TPPS2a-PCI of 100 nM scFvMEL/rGel or rGel/nGel in A-375
cells (PS-concentration: 0.2 mg/ml). Cells were treated as
described in the Materials and Methods, however the MTT assay
was performed 24 hours and not 48 hours, post light exposure.
Bars, SD.
Found at: doi:10.1371/journal.pone.0006691.s002 (0.04 MB PPT)
Figure S3 EGFP signals post PDT and PCI 24 and 48 hours
after light exposure. The reduction of EGFP signals after PCI of
scFvMEL/rGel is much more pronounced 48 hours than at
24 hours post light exposure, while no differences in green
fluorescence between 24 and 48 hours post PDT was detected.
Cells treated with PDT, as shown in the first and third row are
either dead, dying or alive, while cells treated with PCI are most
truly dying or dead. Representative fluorescence micrographs are
shown for each time point. Treatment conditions were as
described in Figure 2.
Found at: doi:10.1371/journal.pone.0006691.s003 (9.10 MB PPT)
Figure S4 Cytotoxic response when scFvMEL-rGel was admin-
istered after the photochemical treatment to A-375 cells. The cells
were incubated with 0.2 mg/ml TPPS2a for 18 hours, washed
twice and chased with drug-free medium for 4 hours prior to light
exposure. Immediately after light exposure the cells were treated
with scFvMEL/rGel or rGel (both 100 nM) for 18 hours before
medium was changed with drug-free medium. MTT activity was
measured 48 hours post light exposure. Bars, SD.
Found at: doi:10.1371/journal.pone.0006691.s004 (0.04 MB PPT)
Figure S5 Detection of selective binding of scFvMEL/rGel to
MA11 cells. A, Cells were incubated with 80 nM scFvMEL/rGel
Light-Enhanced Drug Delivery
PLoS ONE | www.plosone.org 8 August 2009 | Volume 4 | Issue 8 | e6691on ice for 30 min. Cells were then washed twice with ice cold
medium and further incubated with a rabbit anti-gelonin antibody
(1:50 dilution) for 30 min on ice. Subsequently, the cells were
washed twice with ice cold medium and further incubated with a
secondary Alexa488 labeled goat anti-rabbit antibody (1:100) and
incubated on ice for 30 min. The cells were then washed twice
with ice cold PBS (w.Ca2+) and subjected to fluorescence
microscopy. B, Control binding. Cells that were not incubated
with scFvMEL/rGel bit received the same antibody treatment as
described above. The same fluorescence intensity range was set for
all micrographs.
Found at: doi:10.1371/journal.pone.0006691.s005 (1.02 MB PPT)
Figure S6 Assessment of the weights of the animals. The body
weights of the mice were monitored twice weekly. Mice were
treated as indicated in the figure and otherwise described in
Figure 5.
Found at: doi:10.1371/journal.pone.0006691.s006 (0.05 MB PPT)
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